Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,922,201 papers from all fields of science
Search
Sign In
Create Free Account
LYPD6B gene
Known as:
LYPD7
, LY6/PLAUR domain containing 6B
, CT116
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract CT116: Phase I/II study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma
Zhongping Chen
,
Chengcheng Guo
,
+7 authors
Dennis Brown
Clinical Trials
2019
Corpus ID: 219269991
Glioblastoma (GBM) is the most common and aggressive primary brain cancer. Current standard-of-care includes surgery followed by…
Expand
2018
2018
Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1…
R. Ferris
,
G. Blumenschein
,
+18 authors
M. Gillison
Clinical Trials
2018
Corpus ID: 81211399
Aim: Nivo is the only immunotherapy to significantly improve overall survival (OS) in patients (pts) with R/M SCCHN who have…
Expand
2016
2016
Abstract CT116: Dynamics of cytotoxic T-cell subsets during immunotherapy predicts outcome in acute myeloid leukemia
F. E. Sander
,
Anna Rydström
,
+7 authors
A. Martner
2016
Corpus ID: 79050593
Preventing relapse after the completion of chemotherapy remains a challenge in acute myeloid leukemia (AML), in particular in…
Expand
2015
2015
Nicotinic Signaling: Alpha3 Beta4 Heteromers, Alpha5 Subunits, And The Prototoxin Lypd6b
Vanessa Ochoa
2015
Corpus ID: 147913808
Prototoxin proteins have been identified as members of the Ly6/uPAR super family whose three-finger motif resembles that of…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE